Shionogi Pharmaceuticals Applies For Approval Of ARB Irbetan And Compounding Agent
This article was originally published in PharmAsia News
Shionogi Pharmaceuticals announced July 30 it applied for the approval of the high blood pressure drug Irbetan (irbesartan) and the diuretic Fluitran (trichlormethiazide) in Japan.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.